ZyVersa Therapeutics Azioni (NASDAQ: ZVSA)

Ultime notizie per ZyVersa Therapeutics (NASDAQ:ZVSA) Azioni

ZyVersa Therapeutics

ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.

ZyVersa Therapeutics, Inc. - Common Stock

ZyVersa Therapeutics Inc

BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.07) by 28.57 percent. The company reported quarterly sales of $41.505 million which missed the analyst consensus estimate of $46.030 million by 9.83 percent. This is a 22.12 percent increase over sales of $33.988 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

BBAI

BigBear.ai Hldgs Q3 2024 GAAP EPS $(0.05) Beats $(0.07) Estimate, Sales $41.505M Miss $46.030M Estimate

Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.65 by 27.69 percent. The company reported quarterly sales of $625.71 million which beat the analyst consensus estimate of $603.93 million by 3.61 percent. This is a 63.10 percent increase over sales of $383.64 million the same period last year.

GMED

Globus Medical Q3 2024 Adj EPS $0.83 Beats $0.65 Estimate, Sales $625.71M Beat $603.93M Estimate

WIIM

B&G Foods shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 net sales guidance below estimates.

Acadia Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) today announced that it entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction.
Acadia was granted the PRV in March 2023 following approval by the U.S. Food and Drug Administration (FDA) of DAYBUE&#x2122; (trofinetide) for the treatment of Rett syndrome. DAYBUE was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018. Pursuant to the license agreement, Acadia is required to pay Neuren one-third of the net proceeds.
Acadia plans to invest proceeds from the sale of the PRV to support its commercial operations, R&amp;D programs in central nervous system and rare disease, and future business development.
The transaction is subject to customary closing conditions, including expiration of applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Jefferies LLC acted as financial advisor to Acadia on this transaction.

Asset Sales

ACAD

Acadia Pharmaceuticals Enters Into An Agreement To Sell Its Rare Pediatric Disease Priority Review Voucher For $150M

Gulf Island Fabrication (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIFI#NASDAQ">GIFI</a>) reported quarterly earnings of $0.14 per share. The company reported quarterly sales of $37.640 million which missed the analyst consensus estimate of $42.000 million by 10.38 percent. This is a 649.35 percent increase over sales of $5.023 million the same period last year.

GIFI

Gulf Island Fabrication Q3 2024 GAAP EPS $0.14, Sales $37.640M Miss $42.000M Estimate

Ternium Q3 2024 EPADS $0.16, Sales $4.480B Beat $4.446B Estimate

New preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM) and enhanced potency to better target solid tumors will be presented at SITC
Additional profiling of patient responses in P-BCMA-ALLO1 Phase 1 Arm C and preclinical P-CD19CD20-ALLO1 to be presented at ASH
SAN DIEGO, Nov. 5, 2024 /PRNewswire/ --&nbsp;Poseida Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced new preclinical data on allogeneic CAR+TCR-T cells rich in stem cell memory T cells (TSCM), along with platform enhancements aimed at enhancing potency and improving targeting of solid tumors, will be presented at the Society for Immunotherapy of Cancer (SITC) 39th&nbsp;Annual Meeting in Houston, November 6-10.

Biotech

General

PSTX

Poseida Therapeutics To Present Clinical And Preclinical Data On Investigational Allogeneic CAR-T Cell Therapies At SITC 2024 And ASH 2024

Guidance

QLYS

Qualys Expects Q4 Adj EPS Of $1.28 - $1.38 (Est $1.28), Revenues Of $154.5M - $157.5M (Est $154.059M)

MGNX

MacroGenics shares are trading higher after the company reported better-than-expected Q3 financial results.

International Flavors & Fragrances Sees FY24 Sales $11.3B-$11.4B Vs $11.288B Est.

–&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Real World Study Compared Over 150,000 Adult &amp; Pediatric Patients – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor Associated with Fewer Adverse Drug Reactions – –&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Caldolor also Improved Healthcare Utilization –
NASHVILLE, Tenn., Nov. 5, 2024 /PRNewswire/ -- Specialty pharmaceutical company Cumberland Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) today announced the publication of new real-world outcomes research demonstrating the safety and healthcare resource advantages of its Caldolor (ibuprofen) injection over ketorolac in both adult and pediatric populations. The study, published in Frontiers of Pain Research, provides compelling evidence that Caldolor is associated with a significantly reduced incidence of adverse drug reactions (ADRs) and improved healthcare utilizations when compared to ketorolac.
This extensive, retrospective, payer database analysis evaluated the records of over 17 million patients who had received either ketorolac or Caldolor. Ultimately, 31,046 Caldolor and 124,184 ketorolac adult patients were selected and compared for ADRs and subsequent healthcare resource utilization, which includes inpatient, outpatient and emergency department visits as well as all procedures and prescriptions during the follow up time of 29 days. An additional 5,579 pediatric patients were identified in each arm and compared in a separate claims analysis.
Key findings reveal that, in adults, Caldolor was associated with a 45% reduction in renal dysfunction (p&lt;0.001) and a 78% decrease in hematuria rates (p&lt;0.001) when compared to ketorolac. Notably, patients also experienced fewer gastrointestinal complications as well as reduced headaches, nausea and abdominal pain. Among pediatric patients, the results showed Caldolor was associated with a 51-65% lower rate of ADRs, including headache and nausea, with 95% confidence intervals supporting clinical significance.
Caldolor also demonstrated a positive impact on healthcare resource utilization (HCRU) when compared to ketorolac, with decreased emergency room and outpatient visits, as well as a shortened hospital length of stay for both adults and children.

CPIX

Cumberland Pharmaceuticals Announces The Publication Of New Real-World Outcomes Research Demonstrating The Safety And Healthcare Resource Advantages Of Its Caldolor (Ibuprofen) Injection Over Ketorolac In Both Adult And Pediatric Populations

AVNW

Aviat Networks shares are trading lower after the company reported worse-than-expected Q1 financial results and lowered its FY25 sales guidance.

Forrester Res (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORR#NASDAQ">FORR</a>) affirms FY2024 Adj EPS guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 analyst estimate. Affirms FY2024 sales outlook from $425.00 million-435.00 million to $425.00 million-435.00 million vs $430.33 million estimate.

FORR

Forrester Res Affirms FY2024 Adj EPS Guidance from $1.37-1.57 to $1.37-1.57 vs $1.46 Est; Affirms FY2024 Sales Guidance from $425.00M-435.00M to $425.00M-435.00M vs $430.33M Est.

Sixth Street Specialty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSLX#NYSE">TSLX</a>) reported quarterly earnings of $0.57 per share which met the analyst consensus estimate. This is a 5 percent decrease over earnings of $0.60 per share from the same period last year. The company reported quarterly sales of $119.223 million which beat the analyst consensus estimate of $118.508 million by 0.60 percent. This is a 4.18 percent increase over sales of $114.435 million the same period last year.

TSLX

Sixth Street Specialty Q3 2024 Adj. EPS $0.57, Inline, Sales $119.223M Beat $118.508M Estimate

Weyco Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) reported quarterly earnings of $0.84 per share. This is a 14.29 percent decrease over earnings of $0.98 per share from the same period last year. The company reported $74.33 million in sales this quarter. This is a 11.67 percent decrease over sales of $84.15 million the same period last year.

WEYS

Weyco Group Q3 EPS $0.84 Down From $0.98 YoY, Sales $74.33M Down From $84.15M YoY

Intl Flavors &amp; Fragrances (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>) reported quarterly earnings of $1.04 per share which missed the analyst consensus estimate of $1.08 by 3.7 percent. The company reported quarterly sales of $2.92 billion which beat the analyst consensus estimate of $2.83 billion by 3.29 percent. This is a 3.72 percent increase over sales of $2.82 billion the same period last year.

Intl Flavors & Fragrances Q3 2024 Adj EPS $1.04 Misses $1.08 Estimate, Sales $2.92B Beat $2.83B Estimate

Weyco Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WEYS#NASDAQ">WEYS</a>) (the "Company") announced that today its Board of Directors declared a special one-time cash dividend of $2.00 per share, for a total of approximately $19.0 million based on the number of shares currently outstanding. The dividend will be paid on January 2, 2025, to shareholders of record at the close of business on November 18, 2024.

Dividends

Weyco Group Declares Special Cash Dividend Of $2.00 Per Share, For A Total Of ~$19M Based On The Number Of Shares Currently Outstanding

Offerings

PLBY

Playboy Announced The Closing Of Its Sale Of 14.9M Newly Issued Shares In A Private Placement At A Price Of $1.50 Per Share For A Total Purchase Price Of $22.35M

SMCI

Super Micro Computer shares are trading lower after the company lowered its financial outlook.

MCHP

Microchip Sees Q3 2024 Adj. EPS $0.29-$0.32

ZyVersa Therapeutics GAAP EPS of -$3.31 beats by $0.44

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ZyVersa Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/zvsa-stock-quote/">ZVSA</a>) just reported results for the second quarter of 2024.<ul><li>ZyVersa Therapeutics reported earnings per share of -$3.31. This was above the analyst estimate for EPS of -$3.75.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/zvsa-stock-earnings-zyversa-therapeutics-for-q2-of-2024/">ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024

ZyVersa Therapeutics files for mixed shelf offering

Warning: ZVSA is at high risk of performing badly

ZyVersa Therapeutics (ZVSA) highlights data from a review article published in the peer-reviewed journal, Life. The article summarizes data from 34...

ZyVersa highlights review article on inflammasome-induced inflammation

An announcement from ZyVersa Therapeutics ( ($ZVSA) ) is now available. ZyVersa Therapeutics' recent annual meeting saw key shareholder approvals, ...

ZyVersa Therapeutics' Shareholder Approvals and Director Elections

ZVSA

Screenshot 2024-03-29 at 1.05.42 AM

CEO Of This Leading Biotech Speaks To The Critical Nature Inflammation Plays In The Body

Health Care

Press Releases

ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults

ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation

ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications

ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors

ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months

Analyst Ratings

ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases

ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs

ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes

"Trump Media (NASDAQ: DJT) Surges on Election Day as SmallCap Stocks CRDL, ALBT, ZVSA, PRSO Emerge"

ALBT

CRDL

PRSO

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

Apollomics

Bone Biologics

Bionomics Limited - American Depository Shares

Bionomics

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Molecular Templates

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Protagenic Therapeutics, Inc. - Common Stock

Protagenic Therapeutics

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Scorpius Holdings

Salarius Pharmaceuticals, Inc. - Common Stock

Salarius Pharmaceuticals

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Theriva Biologics

Windtree Therapeutics, Inc. - Common Stock

Windtree Therapeutics

HC Wainwright & Co.

ZyVersa Therapeutics shares are trading higher after the company highlighted data showing the potential of inflammasome inhibition to protect pancreatic islet beta cells and attenuate progression from obesity to insulin resistance and type 2 diabetes.

Comments

ZyVersa Therapeutics

Notizie

Ultime notizie per ZyVersa Therapeutics (NASDAQ:ZVSA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO